Clinical Trial Update: A Safety and Tolerability Study of Peginesatide in Anemic Cancer Patients Receiving Cytotoxic Chemotherapy. [Phase 1]

View source ↗

Summary

Phase 1 safety and tolerability study of peginesatide in anemic cancer patients receiving cytotoxic chemotherapy has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia

Drugs mentioned

• Peginesatide (peginesatide)

Snippet

Sponsor: Takeda | Conditions: Anemia | Phase 1 | Status: TERMINATED